UBS Picks Elanco As The Strongest Animal Health Setup
UBS said Elanco Animal Health is its strongest animal health pick for Q2, citing US pet healthcare momentum through May and early market share gains for Credelio Quattro. UBS expects Q2 revenue above expectations and a potential full-year guidance raise, kept a buy rating and set a $31 price target versus $25.33. UBS was neutral on IDEXX and Zoetis.
How this was made
The 30-second read
Why it matters
The trading relevance is mainly through expectations for a potential full-year guidance raise at Elanco, which could drive model updates and valuation changes.
Market read
Relative positioning within animal health tilts toward Elanco on the specific thesis that management could lift full-year guidance if US pet momentum and Credelio Quattro sales continue.
What to watch
The article does not provide quantified Credelio Quattro sales, competitive dynamics, or any management commentary, so the guidance-raise probability may be overstated.
Background
UBS issued an animal health preview ahead of Q2 earnings, ranking Elanco as the strongest setup and keeping IDEXX and Zoetis at neutral.
Ticker impact
UBS keeps IDEXX Laboratories at neutral, saying it looks steadier but lacks clearer catalysts for meaningful upside.
Lower probability of near-term rerating versus bullish peers, absent new IDEXX-specific catalysts.
The note is comparative and does not disclose new IDEXX fundamentals or guidance.
UBS keeps Zoetis at neutral, arguing it is steadier but needs clearer catalysts to deliver meaningful upside.
Muted near-term sentiment impact unless subsequent events confirm a catalyst.
This is an analyst positioning call, not a fresh Zoetis operational or guidance update.
Market effects
Shifts relative sentiment within animal health toward US pet healthcare momentum and Credelio Quattro execution as the key near-term driver.
Emphasizes US pet health demand through May as the primary read-through for Q2.
Limited direct global read-through; focus is on US momentum and product share gains.
Counterpoint
A guidance raise is not guaranteed; if Credelio Quattro share gains or US pet demand slow, the note’s upside case could fail quickly.
Key entities
- companyElanco Animal Health
UBS’s top animal health pick for Q2, citing US pet healthcare momentum and early Credelio Quattro share gains.
- productCredelio Quattro
UBS cites early market share gains for this treatment as a driver of Elanco’s Q2 outlook.
- companyIDEXX Laboratories
UBS rates neutral, saying it looks steadier but needs clearer catalysts for upside.
- companyZoetis
UBS rates neutral, saying it needs clearer catalysts despite steadier fundamentals.
- institutionUBS
Investment bank issuing the preview and price target framework discussed in the article.
